ATE514695T1 - Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren - Google Patents

Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren

Info

Publication number
ATE514695T1
ATE514695T1 AT07804890T AT07804890T ATE514695T1 AT E514695 T1 ATE514695 T1 AT E514695T1 AT 07804890 T AT07804890 T AT 07804890T AT 07804890 T AT07804890 T AT 07804890T AT E514695 T1 ATE514695 T1 AT E514695T1
Authority
AT
Austria
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AT07804890T
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Dress
Jacqui Hoffman
Mary Johnson
Robert Kania
Phuong Le
Mitchell NAMBU
Mason Pairish
Michael Plewe
Khanh Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE514695T1 publication Critical patent/ATE514695T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
AT07804890T 2006-09-15 2007-09-03 Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren ATE514695T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (1)

Publication Number Publication Date
ATE514695T1 true ATE514695T1 (de) 2011-07-15

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07804890T ATE514695T1 (de) 2006-09-15 2007-09-03 Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren

Country Status (42)

Country Link
US (3) US7696213B2 (de)
EP (1) EP2074122B9 (de)
JP (1) JP4718637B2 (de)
KR (1) KR101099926B1 (de)
CN (1) CN101573358B (de)
AP (1) AP2710A (de)
AR (1) AR062785A1 (de)
AT (1) ATE514695T1 (de)
AU (1) AU2007297212B8 (de)
BR (1) BRPI0716749B8 (de)
CA (1) CA2663401C (de)
CL (1) CL2007002682A1 (de)
CR (1) CR10662A (de)
CU (1) CU23783B7 (de)
CY (1) CY1111911T1 (de)
DK (1) DK2074122T5 (de)
DO (1) DOP2009000039A (de)
EA (1) EA016388B1 (de)
ES (1) ES2366489T3 (de)
GE (1) GEP20115306B (de)
GT (1) GT200700077A (de)
HK (1) HK1138589A1 (de)
HN (1) HN2007000267A (de)
HR (1) HRP20110621T2 (de)
IL (1) IL197243A (de)
MA (1) MA30709B1 (de)
ME (1) MEP8009A (de)
MX (1) MX2009002927A (de)
MY (1) MY146420A (de)
NI (1) NI200900032A (de)
NO (1) NO342357B1 (de)
NZ (1) NZ575167A (de)
PE (1) PE20080670A1 (de)
PL (1) PL2074122T3 (de)
PT (1) PT2074122E (de)
RS (2) RS51927B (de)
SI (1) SI2074122T1 (de)
TN (1) TN2009000085A1 (de)
TW (1) TWI334353B (de)
UY (1) UY30588A1 (de)
WO (1) WO2008032162A1 (de)
ZA (1) ZA200901477B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP8009A (en) 2006-09-15 2011-12-20 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
JP2010523670A (ja) * 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
BRPI0915901A2 (pt) * 2008-07-11 2015-10-27 Novartis Ag combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
AU2009282574B2 (en) * 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (de) 2008-08-20 2011-06-01 Schering Corporation Substituierte pyridin- und pyrimidinderivate und ihre verwendung bei der behandlung von virusinfektionen
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8101622B2 (en) * 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
EP2813506B1 (de) 2010-12-16 2016-05-25 F. Hoffmann-La Roche AG Tricyclische PI3K-Hemmerverbindungen und Verfahren zur Verwendung
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
JP6058009B2 (ja) 2011-08-31 2017-01-11 ノバルティス アーゲー Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
AU2015329625B2 (en) 2014-10-10 2018-04-05 Pfizer Inc. Synergistic auristatin combinations
LT3302565T (lt) 2015-06-04 2019-12-27 Pfizer Inc. Kietos palbociklibo dozavimo formos
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
ES2876411T3 (es) 2016-08-15 2021-11-12 Pfizer Inhibidores de piridopirimdinona CDK2/4/6
WO2018112176A1 (en) * 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
CA3238551A1 (en) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
US20040224958A1 (en) 2000-01-27 2004-11-11 Booth Richard John Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE60144322D1 (de) 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
CN1503797A (zh) 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
ATE370952T1 (de) 2002-04-19 2007-09-15 Smithkline Beecham Corp Neue verbindungen
NZ536123A (en) 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
DK1648889T3 (da) 2003-07-11 2009-01-05 Warner Lambert Co Isethionatsalt af en selektiv CDK4-inhibitor
KR20060097105A (ko) 2003-07-22 2006-09-13 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나아제 저해제로서의 퀴놀리논 유도체
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4989233B2 (ja) 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2005082903A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0510560A (pt) * 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
JP2008501677A (ja) 2004-06-04 2008-01-24 ファイザー・プロダクツ・インク 異常な細胞増殖を治療する方法
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EP2322523B1 (de) * 2005-10-07 2019-01-02 Exelixis, Inc. Verfahren zur Herstellung von Pyridopyrimidinon-Inhibitoren von PI3Kalpha
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EP1872922A1 (de) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Verfahren und Vorrichtung zur Herstellung eines Kunststoff-Gegenstandes
EP2056829B9 (de) 2006-08-16 2012-09-26 Exelixis, Inc. Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
MEP8009A (en) * 2006-09-15 2011-12-20 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
NZ579480A (en) * 2007-03-14 2012-03-30 Exelixis Patent Co Llc 2-Arylamino-quinazoline derivatives
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US8101622B2 (en) * 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations

Also Published As

Publication number Publication date
TN2009000085A1 (fr) 2010-08-19
BRPI0716749A2 (pt) 2014-02-18
NO342357B1 (no) 2018-05-14
RS51927B (en) 2012-02-29
US20120309775A1 (en) 2012-12-06
CA2663401A1 (en) 2008-03-20
US20080090801A1 (en) 2008-04-17
KR20090040389A (ko) 2009-04-23
HRP20110621T2 (hr) 2013-12-06
US20100137279A1 (en) 2010-06-03
UY30588A1 (es) 2008-05-02
AP2710A (en) 2013-07-30
JP2010503653A (ja) 2010-02-04
IL197243A (en) 2013-07-31
ZA200901477B (en) 2010-07-28
AP2009004790A0 (en) 2009-04-30
TW200820972A (en) 2008-05-16
ES2366489T3 (es) 2011-10-20
PE20080670A1 (es) 2008-06-14
EP2074122A1 (de) 2009-07-01
HRP20110621T1 (en) 2011-09-30
AR062785A1 (es) 2008-12-03
KR101099926B1 (ko) 2011-12-28
CA2663401C (en) 2011-07-12
DK2074122T5 (da) 2014-03-17
CU23783B7 (es) 2012-02-15
NI200900032A (es) 2010-05-14
AU2007297212A1 (en) 2008-03-20
US8273755B2 (en) 2012-09-25
HK1138589A1 (en) 2010-08-27
MY146420A (en) 2012-08-15
WO2008032162A8 (en) 2009-03-26
AU2007297212B2 (en) 2011-04-14
US7696213B2 (en) 2010-04-13
DOP2009000039A (es) 2015-12-15
CL2007002682A1 (es) 2008-04-04
JP4718637B2 (ja) 2011-07-06
WO2008032162A1 (en) 2008-03-20
NZ575167A (en) 2010-10-29
CN101573358B (zh) 2012-05-30
SI2074122T1 (sl) 2011-10-28
GT200700077A (es) 2009-08-03
ES2366489T9 (es) 2013-12-27
TWI334353B (en) 2010-12-11
GEP20115306B (de) 2011-10-10
MEP8009A (en) 2011-12-20
EA200970207A1 (ru) 2009-08-28
MX2009002927A (es) 2009-03-31
HN2007000267A (es) 2011-02-25
CU20090040A7 (es) 2011-07-11
CY1111911T1 (el) 2015-11-04
AU2007297212B8 (en) 2011-04-28
NO20091141L (no) 2009-03-31
EP2074122B9 (de) 2013-09-11
MA30709B1 (fr) 2009-09-01
BRPI0716749B1 (pt) 2020-10-06
BRPI0716749B8 (pt) 2021-05-25
DK2074122T3 (da) 2011-08-15
PT2074122E (pt) 2011-08-24
RS20090104A (en) 2010-06-30
EP2074122B1 (de) 2011-06-29
IL197243A0 (en) 2009-12-24
CN101573358A (zh) 2009-11-04
EA016388B1 (ru) 2012-04-30
PL2074122T3 (pl) 2011-10-31
CR10662A (es) 2009-04-17
US8633204B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
ATE514695T1 (de) Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
IL197231A0 (en) Pyrimidines derivatives and their use as kinase inhibitors
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
DE602007013295D1 (de) Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
IL196775A0 (en) 2 - METHYLMORPHOLINE PYRIDO-PYRAZO - AND PYRIMIDO -, PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
SI1926722T1 (sl) Substituirani benzimidazoli kot kinazni inhibitorji
PT2428513T (pt) Derivados de quinazolinona substituídos em 5 como agentes anticancro
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE602007005111D1 (de) Pyridazinonverbindung und ihre verwendung als herbizid
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
EP1713793A4 (de) Pyrimidinonverbidnungen, die sich als kinaseinhibitoren eignen
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE468338T1 (de) Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer
ATE513817T1 (de) Pyrimidinderivate und ihre verwendung als pestizide
ATE435865T1 (de) Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ATE500223T1 (de) Phenylpentadienoylderivate und ihre verwendung als par-1-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2074122

Country of ref document: EP